Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 11/20 | 1.00 |
| ▸ | GRIN3B | O60391 | 11/20 | 1.00 |
| ▸ | GRIN1 | Q05586 | 11/20 | 1.00 |
| ▸ | GRIN2A | Q12879 | 11/20 | 1.00 |
| ▸ | GRIN2B | Q13224 | 11/20 | 1.00 |
| ▸ | GRIN2C | Q14957 | 11/20 | 1.00 |
| ▸ | GRIN3A | Q8TCU5 | 11/20 | 1.00 |
| ▸ | GRIA1 | P42261 | 4/20 | 0.64 |
| ▸ | GRIA2 | P42262 | 4/20 | 0.64 |
| ▸ | GRIA3 | P42263 | 4/20 | 0.64 |
| ▸ | GRIA4 | P48058 | 4/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | BLM | P54132 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5769722 | 0.83 | GRIN2D (1.00) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL762964 | 0.82 | GRIN2D (0.70) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL24715694 | 0.81 | GRIN2D (0.75) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL30807512 | 0.81 | GRIN2D (0.67) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL30807513 | 0.81 | GRIN2D (0.67) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL24876001 | 0.79 | GRIN2D (0.64) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL14326945 | 0.79 | GRIN2D (0.76) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL10045971 | 0.78 | GRIN2D (0.63) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL24875986 | 0.78 | GRIN2D (0.61) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL24875976 | 0.76 | GRIN2D (0.59) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160152616-A1 | NOVEL TRICYCLIC COMPOUNDS AND PROCESS FOR PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-06-02 | — | — | US | claimed |
| CN-116528867-A | Compounds for the treatment of Alzheimer's disease | 艾伯塔大学理事会 | 2023-08-01 | — | — | CN | disclosed |
| EP-2696873-B1 | PLASMODIAL SURFACE ANION CHANNEL INHIBITORS FOR THE TREATMENT OR PREVENTION OF MALARIA | US HEALTH (US) | 2022-08-03 | — | — | EP | disclosed |
| US-20210085679-A1 | PLASMODIAL SURFACE ANION CHANNEL INHIBITORS FOR THE TREATMENT OR PREVENTION OF MALARIA | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-03-25 | — | — | US | disclosed |
| US-10869865-B2 | Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2020-12-22 | — | — | US | disclosed |
| CN-111808033-B | Preparation method and application of novel compound with antibacterial effect | 江西中医药大学 | 2020-12-15 | — | — | CN | disclosed |
| CN-111808033-A | Preparation method and application of novel compound with antibacterial effect | 江西中医药大学 | 2020-10-23 | — | — | CN | disclosed |
| US-20190183889-A1 | PLASMODIAL SURFACE ANION CHANNEL INHIBITORS FOR THE TREATMENT OR PREVENTION OF MALARIA | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2019-06-20 | — | — | US | disclosed |
| US-10265313-B2 | Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2019-04-23 | — | — | US | disclosed |
| EP-3019498-B1 | NOVEL TRICYCLIC COMPOUNDS AND PROCESS FOR PREPARATION THEREOF | COUNCIL SCIENT IND RES (IN) | 2018-12-26 | — | — | EP | disclosed |
| WO-2010124826-A1 | SUBSTITUTED IMIDAZOQUINOXALINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-11-04 | — | — | WO | disclosed |
| EP-0783495-B1 | QUINOXALINE DERIVATIVES USEFUL IN THERAPY | PFIZER LTD (GB) | 2002-02-27 | — | — | EP | disclosed |
| US-6251903-B1 | Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones and the use thereof as glycine receptor antagonist | COCENSYS, INC. | 2001-06-26 | — | — | US | disclosed |
| US-6147075-A | ANALGESICS; PSYCHOLOGICAL DISORDERS | COCENSYS, INC. (US) | 2000-11-14 | — | — | US | disclosed |
| US-5977107-A | Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones and the use thereof as glycine receptor antagonists | COCENSYS, INC. (US) | 1999-11-02 | — | — | US | disclosed |
| US-5863917-A | ANXIOLYTIC AGENT, ANTICONVULSANTS, ANALGESICS AND NEUROPROTECTIVES. | PFIZER, INC. (US) | 1999-01-26 | — | — | US | disclosed |
| US-5852016-A | Quinoxaline derivatives useful in therapy | PFIZER INC. (US) | 1998-12-22 | — | — | US | disclosed |
| EP-0792874-A1 | Quinoxaline derivatives useful in therapy | Pfizer Limited (GB) | 1997-09-03 | — | — | EP | disclosed |
| US-5631373-A | NERVOUS SYSTEM DISORDERS | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) | 1997-05-20 | — | — | US | disclosed |
| WO-1996009295-A1 | QUINOXALINE DERIVATIVES USEFUL IN THERAPY | PFIZER LIMITED (GB) | 1996-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10265313-B2 | Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria | CLIC1, SLC47A2, SLC47A1 | GRIN2D 2224/4885GRIN3B 1259/4885GRIN1 1516/4885 |
| US-10869865-B2 | Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria | CLIC1, SLC47A2, SLC47A1 | GRIN2D 2224/4885GRIN3B 1259/4885GRIN1 1516/4885 |
| US-20160152616-A1 | NOVEL TRICYCLIC COMPOUNDS AND PROCESS FOR PREPARATION THEREOF | CCKAR, HKDC1, NRDC | GRIN2D 1982/4885GRIN3B 1881/4885GRIN1 1945/4885 |
| US-20210085679-A1 | PLASMODIAL SURFACE ANION CHANNEL INHIBITORS FOR THE TREATMENT OR PREVENTION OF MALARIA | CLIC1, SLC47A2, SLC47A1 | GRIN2D 2224/4885GRIN3B 1259/4885GRIN1 1516/4885 |
| US-20190183889-A1 | PLASMODIAL SURFACE ANION CHANNEL INHIBITORS FOR THE TREATMENT OR PREVENTION OF MALARIA | CLIC1, SLC47A2, SLC47A1 | GRIN2D 2224/4885GRIN3B 1259/4885GRIN1 1516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.